Krystal Biotech has been granted a patent for a pharmaceutical composition containing a recombinant herpes simplex virus type 1 (HSV-1) with polynucleotides encoding IL-2 and IL-12 polypeptides for cancer treatment. The composition includes pharmaceutically acceptable excipients. GlobalData’s report on Krystal Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Krystal Biotech, Oncolytic viruses was a key innovation area identified from patents. Krystal Biotech's grant share as of February 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for cancer treatment using recombinant hsv-1 virus
A recently granted patent (Publication Number: US11918660B2) discloses a pharmaceutical composition comprising a herpes simplex virus type 1 (HSV-1) with a recombinant genome encoding Interleukin (IL)-2 and IL-12 polypeptides. The IL-12 polypeptide consists of alpha and beta subunits connected by a linker polypeptide, with specific promoters linked to the encoding polynucleotides. The composition excludes mutations in certain HSV-1 genes and is not intended for oncolytic purposes, offering a range of administration routes.
Furthermore, the patent covers a pharmaceutical composition with a population of HSV-1 viruses containing recombinant genomes encoding IL-2 and IL-12 polypeptides. The composition can consist of replication-defective or replication-competent viruses, with the polynucleotides for IL-2 and IL-12 located within the same genome. The linker polypeptide can be cleavable or non-cleavable, with specific sequence identity requirements. This innovative composition opens up possibilities for therapeutic applications beyond traditional vaccines, with potential implications for various medical treatments.
To know more about GlobalData’s detailed insights on Krystal Biotech, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
